Anisodamine Hydrobromide Protects Glycocalyx and Against the Lipopolysaccharide-Induced Increases in Microvascular Endothelial Layer Permeability and Nitric Oxide Production
Authors:
- 15 September 2020
- journal article
- research article
- Published by Springer Nature in Cardiovascular Engineering and Technology
- Vol. 12 (1) , 91-100
Abstract
Purpose Anisodamine hydrobromide (Ani HBr) has been used to improve the microcirculation during cardiovascular disorders and sepsis. Glycocalyx plays an important role in preserving the endothelial cell (EC) barrier permeability and nitric oxide (NO) production. We aimed to test the hypothesis that Ani HBr could protect the EC against permeability and NO production via preventing glycocalyx shedding. Methods A human cerebral microvascular EC hCMEC/D3 injury model induced by lipopolysaccharide (LPS) was established. Ani HBr was administrated to ECs with the LPS challenge. Cell viability was performed by Cell Counting Kit-8 assay. Cell proliferation and apoptosis were detected by EdU and Hoechst 33342 staining. Apoptosis and cell cycle were also assessed by flow cytometry with annexin V staining and propidium iodide staining, respectively. Then, adherens junction integrity was evaluated basing on the immunofluorescence staining of vascular endothelial cadherin (VE-cadherin). The glycocalyx component heparan sulfate (HS) was stained in ECs. The cell permeability was evaluated by leakage of fluorescein isothiocyanate (FITC)-dextran. Cellular NO production was measured by the method of nitric acid reductase. Results Ani HBr at 20 μg/mL significantly increased the viability of ECs with LPS challenge, but significantly inhibited the cell viability at 80 μg/mL, showing a bidirectional regulation of cell viability by Ani HBr. Ani HBr had not significantly change the LPS-induced EC proliferation. Ani HBr significantly reversed the induction of LPS on EC apoptosis. Ani HBr reinstated the LPS-induced glycocalyx and VE-cadherin shedding and adherens junction disruption. Ani HBr significantly alleviated LPS-induced EC layer permeability and NO production. Conclusion Ani HBr protects ECs against LPS-induced increase in cell barrier permeability and nitric oxide production via preserving the integrity of glycocalyx. Ani HBr is a promising drug to rescue or protect the glycocalyx.Keywords
Funding Information
- National Natural Science Foundation of China (11402153)
- Chengdu No.1 Pharmaceutical Co., Ltd. (19H0383)
This publication has 47 references indexed in Scilit:
- Heparan sulfate proteoglycan mediates shear stress‐induced endothelial gene expression in mouse embryonic stem cell‐derived endothelial cellsBiotechnology and Bioengineering, 2011
- Synergism between melatonin and atorvastatin against endothelial cell damage induced by lipopolysaccharideJournal of Pineal Research, 2011
- The role of mitosis in LDL transport through cultured endothelial cell monolayersAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- The role of apoptosis in LDL transport through cultured endothelial cell monolayersAtherosclerosis, 2010
- Differential effects of hydrocortisone and TNFα on tight junction proteins in an in vitro model of the human blood–brain barrierThe Journal of Physiology, 2008
- In vitro study of LDL transport under pressurized (convective) conditionsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- The pharmacological properties of anisodamineJournal of Applied Toxicology, 2006
- Blood‐brain barrier‐specific properties of a human adult brain endothelial cell lineThe FASEB Journal, 2005
- Lipopolysaccharide-induced expression of the competence gene KC in vascular endothelial cells is mediated through protein kinase CJournal of Cellular Physiology, 1989
- Anisodamine inhibits thromboxane synthesis, granulocyte aggregation, and platelet aggregation. A possible mechanism for its efficacy in bacteremic shockJAMA, 1982